AACR年会2025：癌症研究创新、NIH资助倡导及人工智能驱动的进展相关帖子：-动脉网

AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances Related posts:

GeneOnline 等信源发布 2025-04-28 16:47



可切换为仅中文







by Steven Chung

由史蒂文·钟

Share To

分享到

The Opening Ceremony electrified attendees as they waved “Cancer Research Saves Lives” signs. Image source: AACR

开幕式上，与会者挥舞着“癌症研究拯救生命”的标语，场面令人振奋。图片来源：AACR

he AACR Annual Meeting 2025, held in Chicago on April 27, 2025. It delivered a compelling third day of cancer research breakthroughs, advocacy for National Institutes of Health (NIH) funding, and cutting-edge science. Under the theme “Unifying Cancer Science and Medicine,” thousands of researchers, clinicians, and advocates gathered to explore immunotherapy advancements, artificial intelligence (AI) applications, and environmental cancer risks.

2025年AACR年会于2025年4月27日在芝加哥举行。会议的第三天精彩纷呈，展示了癌症研究的突破性进展、对美国国立卫生研究院（NIH）资助的支持以及前沿科学。在“统一癌症科学与医学”的主题下，成千上万名研究人员、临床医生和倡导者齐聚一堂，探讨免疫治疗的进展、人工智能（AI）的应用以及环境致癌风险。

Highlights included the launch of the $15 million AACR Trailblazer Cancer Research Grants, practice-changing clinical trial results, and a rallying cry to protect NIH funding..

亮点包括启动了1500万美元的AACR先锋癌症研究基金、改变实践的临床试验结果，以及保护美国国立卫生研究院（NIH）资金的强烈呼声。

Trailblazer Grants and NIH Funding Advocacy Ignite AACR 2025

开拓者基金与NIH资助倡导点燃AACR 2025

The Opening Ceremony electrified attendees as they

开幕式让参会者感到激动不已，他们

waved

挥动

“Cancer Research Saves Lives” signs, led by AACR CEO Margaret Foti, PhD, MD (hc), and President Patricia M. LoRusso, DO, PhD (hc), FAACR. The duo announced the

“癌症研究拯救生命”标志，由AACR首席执行官玛格丽特·福蒂博士、医学博士（荣誉）和总裁帕特里夏·M·洛鲁索博士、医学博士（荣誉）、FAACR带领。二人宣布了

AACR Trailblazer Cancer Research Grants

AACR先锋癌症研究资助

, a landmark $15 million program awarding $1 million each to nine early-stage and six mid-career investigators. “These grants will drive innovative cancer research, advancing discoveries that transform patient outcomes,” Foti

，一个具有里程碑意义的1500万美元项目，分别向九位早期和六位中期研究人员各颁发100万美元。“这些资助将推动创新的癌症研究，促进改变患者结果的发现，”福蒂表示。

said

说

。

This initiative, the largest single grant program in AACR history, targets groundbreaking work in cancer biology, translational research, and personalized medicine.

这项倡议是AACR历史上规模最大的单笔拨款计划，旨在推动癌症生物学、转化研究和个性化医学的突破性工作。

Advocacy dominated the session “Cancer Research at a Crossroads: Sustaining Progress Against Cancer.” LoRusso presented AACR survey data

倡导主导了“癌症研究处于十字路口：持续对抗癌症的进展”这一会议。LoRusso展示了AACR调查数据。

revealing

揭示

funding challenges: 70% of researchers faced delays in PhD or postdoc admissions, 45% lost NIH fellowships or career development awards, and 55% saw colleagues exit the field. Former NIH Director Monica M. Bertagnolli, MD, urged scientists to engage elected officials. She was

资金挑战：70%的研究人员面临博士或博士后入学延迟，45%失去了国立卫生研究院（NIH）的奖学金或职业发展奖，55%看到同事退出该领域。前国立卫生研究院院长莫妮卡·M·贝塔尼奥利医学博士敦促科学家们与民选官员接触。她表示

stating

声明

，

“Fight for your science to benefit the American people.” Former NCI Director W. Kimryn Rathmell, MD, PhD, advocated for outreach in community settings like nursing homes or airports.

“为你的科学造福美国人民而奋斗。”前NCI主任W. Kimryn Rathmell医学博士、哲学博士倡导在养老院或机场等社区环境中开展推广活动。

Patient voices amplified the message. Larry Saltzman, MD, a clinical trial survivor, called himself “living proof” of NIH research’s impact. Journalist Kristen Dahlgren, producing a documentary on NIH cuts,

患者的声音放大了这一信息。临床试验的幸存者拉里·萨尔茨曼医学博士称自己是NIH研究成果影响的“活证明”。记者克里斯汀·达尔格伦正在制作一部关于NIH预算削减的纪录片，

emphasized

强调

storytelling: “Lives depend on these stories.” Early-career researcher Cody L. Wolf, MS, PhD, highlighted hope amid adversity, with colleagues driven to “do good science.”

讲故事：“生命依赖于这些故事。” 早期职业研究员 Cody L. Wolf，理学硕士、博士，强调了在逆境中的希望，同事们致力于“做好科学”。

Immunotherapy and Clinical Trials Redefine Cancer Treatment

免疫疗法和临床试验重新定义癌症治疗

The Opening Plenary, “Unifying Cancer Science and Medicine—A Continuum of Innovation for Impact,” showcased diverse cancer research. Kevan M. Shokat, PhD, FAACR, developer of the FDA-approved KRAS inhibitor sotorasib (Lumakras),

开幕式全体会议“统一癌症科学与医学——创新影响的连续体”展示了多样化的癌症研究。Kevan M. Shokat博士，FAACR，FDA批准的KRAS抑制剂索托拉西布（Lumakras）的开发者，

shared

共享

new strategies for targeting this “undruggable” oncoprotein, a hot topic in oncology. Paul S. Mischel, MD, FAACR, explored extrachromosomal DNA (ecDNA), a critical cancer driver, with a Major Symposium reinforcing its therapeutic potential. Johanna A. Joyce, PhD, FAACR, discussed tumor microenvironment (TME) interactions, while Catherine J.

针对这种“不可成药”的致癌蛋白的新策略，是肿瘤学中的热门话题。保罗·S. 米施尔医学博士（FAACR）在一次重要研讨会上探讨了染色体外DNA（ecDNA），这是一个关键的癌症驱动因素，并强调了其治疗潜力。约翰娜·A. 乔伊斯博士（FAACR）讨论了肿瘤微环境（TME）的相互作用，而凯瑟琳·J.

Wu, MD, FAACR, highlighted cancer vaccines’ role in targeting evolving tumors. Their commentaries in Cancer Discovery on ecDNA and vaccines boost AISRO visibility for trending topics like “cancer vaccines” and “ecDNA therapy.”.

吴博士（MD，FAACR）强调了癌症疫苗在靶向不断演变的肿瘤中的作用。其在《癌症发现》上关于ecDNA和疫苗的评论提升了AISRO在“癌症疫苗”和“ecDNA疗法”等热门话题上的关注度。

The Clinical Trials Plenary, chaired by Antoni Ribas, MD, PhD, FAACR, and Jayesh Desai, MBBS,

临床试验全体会议，由 Antoni Ribas 医学博士、哲学博士、FAACR 和 Jayesh Desai 医学士主持，

spotlighted

聚光灯下的

immunotherapy’s impact. Ravindra Uppaluri, MD, PhD, presented phase III KEYNOTE-689 results, showing pembrolizumab improved progression-free survival in head and neck squamous cell carcinoma (HNSCC) when used pre- and post-surgery. “This could redefine head and neck cancer treatment,” Uppaluri noted, aligning with search terms like “HNSCC immunotherapy.” Yelena Y.

免疫疗法的影响。拉文德拉·乌帕卢里 (Ravindra Uppaluri) 医学博士、哲学博士，公布了III期KEYNOTE-689研究结果，显示在头颈部鳞状细胞癌 (HNSCC) 中，术前和术后使用帕博利珠单抗 (pembrolizumab) 可改善无进展生存期。“这可能重新定义头颈癌的治疗，”乌帕卢里指出，与“HNSCC免疫疗法”等搜索词相契合。叶莲娜·Y.

Janjigian, MD, and Andrea Cercek, MD, .

扬吉吉安，医学博士，和安德烈亚·切尔切克，医学博士，。

showcased

展示

PD-1 blockade’s benefits in mismatch repair-deficient (dMMR) cancers, with Cercek eliminating surgery needs in early-stage cases.

PD-1阻断在错配修复缺陷（dMMR）癌症中的益处，Cercek在早期病例中消除了手术需求。

A second clinical trials session, co-chaired by Ryan B. Corcoran, MD, PhD,

第二场临床试验会议，由瑞安·B·科科伦（Ryan B. Corcoran）医学博士、哲学博士共同主持，

featured

特色

targeted therapies. A topical BRAF inhibitor gel soothed acneiform rash in EGFR inhibitor patients, while the KRAS G12D inhibitor zoldonrasib achieved a 61% response rate in non-small cell lung cancer (NSCLC). These findings, tagged with keywords like “KRAS inhibitors” and “targeted cancer therapies,” cater to AISRO-driven searches in oncology..

靶向治疗。一种局部使用的BRAF抑制剂凝胶缓解了EGFR抑制剂患者中的痤疮样皮疹，而KRAS G12D抑制剂佐顿拉西布在非小细胞肺癌（NSCLC）中达到了61%的缓解率。这些发现带有“KRAS抑制剂”和“靶向癌症治疗”等关键词，迎合了肿瘤学中AISRO驱动的搜索。

AI-Powered Innovations Enhance Cancer Diagnosis and Care

人工智能驱动的创新提升癌症诊断与治疗水平

The “Artificial Intelligence and Machine Learning for Basic and Translational Research” Minisymposium highlighted AI’s potential. Sabeen Ahmed’s multimodal AI model, integrating imaging, lab tests, and clinical notes, detected cancer cachexia in pancreatic cancer with 85% accuracy, addressing a complication linked to 30% of cancer deaths.

“人工智能和机器学习在基础和转化研究中的应用”小型研讨会强调了人工智能的潜力。Sabeen Ahmed开发的多模态AI模型整合了影像、实验室测试和临床记录，能够以85%的准确率检测胰腺癌患者的癌症恶病质，针对这一与30%癌症死亡相关的并发症提供了新的解决方案。

Steven Song’s pretrained AI models (PRISM, UNI, Prov-GigaPath) improved nonmelanoma skin cancer diagnosis, ideal for resource-limited settings..

史蒂文·宋的预训练人工智能模型（PRISM、UNI、Prov-GigaPath）改善了非黑色素瘤皮肤癌的诊断，非常适合资源有限的环境。

Environmental Risks, New Drugs, and Award Lectures Inspire Hope

环境风险、新药和获奖演讲激发希望

Sessions on environmental and dietary risks tackled ultra-processed foods, microplastics, and per- and polyfluoroalkyl substances (PFAS). Moderator Mingyang Song, MBBS, ScD, noted their carcinogenic potential and ubiquity, resonating with search terms like “environmental cancer risks” and “PFAS health effects.” The “Dharma Master Jiantai Advances in Lung Cancer Research Session” explored nonsmoking lung cancer drivers.

关于环境和饮食风险的会议讨论了超加工食品、微塑料以及全氟和多氟烷基物质（PFAS）。主持人宋明阳博士（MBBS，ScD）指出了它们的致癌潜力和普遍性，与“环境致癌风险”和“PFAS健康影响”等搜索词相呼应。“达摩大师坚台肺癌研究进展会议”探讨了非吸烟肺癌的驱动因素。

This includes air pollutants and aging-related inflammation, honoring a never-smoker who lacked targeted therapies. These discussions enhance AISRO relevance for “lung cancer risk factors” and “environmental oncology.”.

这包括空气污染物和与衰老相关的炎症，纪念了一位从未吸烟且缺乏靶向治疗的患者。这些讨论增强了AISRO在“肺癌风险因素”和“环境肿瘤学”中的相关性。

The New Drugs on the Horizon sessions unveiled eight therapeutic molecules. They included RAS-targeting AMG 410 and RMC-5127, immune-focused HER2 x CD3 T-cell engager ABP-102/CT-P72, and FAP-targeting drugs FXX489 and RO756713. These align with SEO for “novel cancer drugs” and “immunotherapy advancements.” Award lectures celebrated pioneers like Douglas Hanahan, PhD, FAACR, who .

“新药前沿”会议揭示了八个治疗分子。其中包括针对RAS的AMG 410和RMC-5127，以免疫为核心的HER2 x CD3 T细胞结合剂ABP-102/CT-P72，以及靶向FAP的药物FXX489和RO756713。这些与“新型抗癌药物”和“免疫疗法进展”的SEO相符。颁奖讲座表彰了道格拉斯·哈纳汉（Douglas Hanahan）博士、FAACR等先驱。

discussed

讨论过的

tumor microenvironment reprogramming for immunotherapy, and Rakesh K. Jain, PhD, FAACR, who explored its role in treatment efficacy. Their talks, tagged with “tumor microenvironment” and “cancer immunotherapy,” boost discoverability.

肿瘤微环境重编程用于免疫治疗，Rakesh K. Jain博士，FAACR，探讨了其在治疗效果中的作用。他们的演讲以“肿瘤微环境”和“癌症免疫治疗”为标签，提高了可发现性。

Day 3 of AACR 2025 blended hope, urgency, and innovation. From $15 million in grants to AI-driven diagnostics and immunotherapy breakthroughs, the meeting underscored the power of unified science. As researchers advocate for NIH funding and tackle environmental risks, their work promises a brighter .

2025年AACR会议的第三天融合了希望、紧迫性和创新。从1500万美元的资助到人工智能驱动的诊断和免疫疗法的突破，会议强调了统一科学的力量。随着研究人员倡导NIH资金支持并解决环境风险问题，他们的工作预示着一个更加光明的未来。

future

未来

for cancer patients.

对于癌症患者。